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Abstract
Purpose The prevalence and consequences of prediabetic
dysglycemia and undiagnosed diabetes is unknown in patients
with heart failure (HF) and preserved ejection fraction
(HFpEF) and has not been compared to heart failure and re-
duced ejection fraction (HFrEF).
Methods We examined the prevalence and outcomes associat-
ed with normoglycemia, prediabetic dysglycemia and diabetes
(diagnosed and undiagnosed) among individuals with a base-
line glycated hemoglobin (hemoglobin A1c, HbA1c) measure-
ment stratified by HFrEF or HFpEF in the Candesartan in
Heart failure Assessment of Reduction in Mortality and mor-
bidity programme (CHARM). We studied the primary out-
come of HF hospitalization or cardiovascular (CV) death,
and all-cause death, and estimated hazard ratios (HR) by use
of multivariable Cox regression models.
Results HbA1c was measured at baseline in CHARM patients
enrolled in the USA and Canada andwas available in 1072/3023
(35%) of patients with HFpEF and 1578/4576 (34%) patients
with HFrEF. 18 and 16%had normoglycemia (HbA1c < 6.0), 20
and 22% had prediabetes (HbA1c 6.0–6.4), respectively. Finally
among patients with HFpEF 22% had undiagnosed diabetes
(HbA1c > 6.4), and 40% had known diabetes (anyHbA1c), with
corresponding prevalence among HFrEF patients being 26 and
35%. The rates of both clinical outcomes of interest were higher
in patients with undiagnosed diabetes and prediabetes, compared
to normoglycemic patients, irrespective of HF subtype, and in
general higher among HFrEF patients. For the primary compos-
ite outcome amongHFpEF patients, the HRs were 1.02 (95%CI
0.63–1.65) for prediabetes, HR 1.18 (0.75–1.86) for undiag-
nosed diabetes and 2.75 (1.83–4.11) for known diabetes, respec-
tively, p value for trend across groups < 0.001. Dysglycemia was
also associated with worse outcomes in HFrEF.
Conclusions These findings confirm the remarkably high
prevalence of dysglycemia in heart failure irrespective of ejec-
tion fraction phenotype, and demonstrate that dysglycemia is
associatedwith a higher risk of adverse clinical outcomes, even
before the diagnosis of diabetes and institution of glucose low-
ering therapy in patients with HFpEF as well as HFrEF.
Keywords Heart failure . Heart failure and preserved ejection
fraction . Diabetes . Dysglycemia . Prognosis
Introduction
People with diabetes have a higher risk of developing incident
heart failure (HF) than those without diabetes [1–3] and among
patients with HF, thosewith diabetes haveworse outcomes than
patients without diabetes [4–6]. The latter observation is of
considerable import because the prevalence of co-existing
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diabetes is high among patients with HF, affecting between 25
and 50% of individuals depending on which study is examined.
Recently, both undiagnosed diabetes and prediabetic
dysglycemia were also found to be common in patients with
HF with reduced ejection fraction (HFrEF) and each was associ-
ated with worse outcomes, compared with normoglycemia, al-
though the risk was not as high as in patients with diagnosed
diabetes [7]. The aim of our study was to determine the preva-
lence and prognostic significance of undiagnosed diabetes and
prediabetic dysglycemia in the other major HF phenotype, HF
with preserved ejection fraction (HFpEF), and compare the prev-
alence and outcomes with those in contemporaneously recruited
patients with HFrEF. To do this, we used data from the
Candesartan in Heart failure: Assessment of Reduction in
Mortality and morbidity (CHARM) programme, which included
patients with HFrEF and HFpEF [6, 8].
Methods
The CHARM-Programme consisted of one HFpEF trial and
two HFrEF trials. CHARM-Preserved enrolled 3023 patients
18 years or older, in York Heart Association (NYHA) func-
tional class II–IV, with a prior hospitalization for a cardiac
reason and a left ventricular ejection fraction (LVEF) above
40% [8]. CHARM-Alternative and CHARM-Added included
2028 and 2548 patients, respectively, aged 18 years or older,
in NYHA functional class II-IV, with a LVEF of 40% or less,
either treated with an angiotensin converting enzyme (ACE)
inhibitor (CHARM-Added) or not, because of intolerance
(CHARM-Alternative) [8]. As previously reported, glycated
hemoglobin (hemoglobin A1c, HbA1c) was measured at
baseline in the 2650 CHARM patients enrolled in Canada
and the USA [6]. We categorized glycemic status in individ-
uals without a history of diabetes using the International
Diabetes Expert Committee criteria: normoglycemia
(HbA1c < 6.0%), prediabetic dysglycemia (HbA1c 6.0–
6.4%) and undiagnosed diabetes (HbA1c > 6.4%) [9].
Patients with a prior diagnosis of diabetes were considered
to have diabetes irrespective of HbA1c level.
We used multivariable Cox proportional hazards models to
evaluate the primary composite outcome of CHARM, which
was death from cardiovascular (CV) causes or a hospitalization
for HF, as well as all-cause mortality, according to glycemic
Table 1 Baseline characteristics
of patients with in CHARM-
Preserved with HbA1c available,
according to glycemic status
No prior diagnosis of diabetes Prior diabetes p value
HbA1c < 6.0 HbA1c 6.0–6.4 HbA1c > 6.4 Any HbA1c
Patients, no (%) 189 (18%) 217 (20%) 238 (22%) 428 (40%)
Age, years 63 ± 12 67 ± 11 69 ± 11 65 ± 11 < 0.001
Female, n (%) 82 (43%) 94 (43%) 100 (42%) 187 (44%) 0.98
HbA1c, median (Q1–Q3) 5.6 (5.5–5.7) 6.1 (6.0–6.2) 6.7 (6.5–7.1) 7.8 (7.1–9.0) < 0.001
NYHA class, n (%) 0.0006
II 105 (56%) 120 (55%) 115 (48%) 168 (39%)
III 81 (43%) 94 (43%) 119 (50%) 246 (57%)
IV 3 (2%) 3 (1%) 4 (2%) 14 (3%)
Ejection fraction 0.56 ± 0.10 0.55 ± 0.09 0.55 ± 0.09 0.54 ± 0.09 0.25
Heart rate, bpm 68 ± 11 69 ± 11 70 ± 12 72 ± 11 < 0.001
SBP, mmHg 132 ± 19 133 ± 17 133 ± 18 134 ± 17 0.86
BMI, kg/m2 29.4 ± 6.4 29.8 ± 6.3 29.8 ± 6.8 32.9 ± 7.1 < 0.001
eGFR, ml/min/1.73m2 82 ± 22 74 ± 23 70 ± 25 69 ± 27 < 0.001
Medical history, n (%)
Ischemic etiology 81 (43%) 108 (50%) 122 (51%) 241 (56%) < 0.001
Prior CABG 39 (21%) 59 (27%) 67 (28%) 144 (34%) < 0.001
Prior PCI 33 (17%) 43 (20%) 52 (22%) 94 (22%) 0.59
Prior stroke 16 (8%) 24 (11%) 19 (8%) 53 (12%) 0.25
Prior AF 51 (27%) 73 (34%) 87 (37%) 121(28%) 0.07
Loop diuretic 110 (58%) 144 (66%) 162 (68%) 319 (75%) < 0.001
Digoxin 56 (30%) 68 (31%) 87 (37%) 158 (37%) 0.21
β-blocker 106 (56%) 123 (57%) 129 (54%) 243 (57%) 0.93
MRA 17 (9%) 22 (10%) 18 (8%) 52 (12%) 0.27
HbA1c hemoglobin A1c, NYHA New York Heart Association functional class, SBP systolic blood pressure, BMI
body mass index, eGFR estimated glomerular filtration rate, CABG coronary artery bypass graft, PCI percutane-
ous coronary intervention, AF atrial fibrillation, MRA mineralocorticoid receptor antagonist
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status. Analyses were adjusted for age, sex, treatment arm,
ejection fraction, NYHA class, heart rate, systolic blood pres-
sure, body mass index (BMI), history of coronary artery by-
pass grafting, percutaneous coronary intervention, implant-
able cardioverter defibrillator, stroke and atrial fibrillation.
Results
HbA1c was available in 1072/3023 (35%) of the patients in
CHARM-Preserved and 428 patients with a HbA1c measure-
ment in this trial had a history of diabetes (Table 1). Patients
with diabetes were older, had a higher BMI, more evidence of
coronary heart disease, worse NYHA class, higher heart rate,
lower estimated glomerular filtration rate (eGFR) and greater
use of loop diuretics compared to those with normoglycemia.
Patients with previously undiagnosed diabetes and those with
prediabetes had a clinical picture in between individuals with
known diabetes and those with normoglycemia (Table 1).
HbA1c was available in 1578/4576 (34%) of individuals in
CHARM-Alternative and CHARM-Added, and 558 patients
in these trials with a HbA1c measurement had a history of
diabetes (Table 2). Similar to what was observed in HFpEF,
we found that patients with known or undiagnosed diabetes
were older, had a worse NYHA class distribution and kidney
function and were more likely to have evidence of coronary
heart disease.
Only 18% of patients with HFpEF and 16% of patients
with HFrEF were normoglycemic.
Prediabetes was more common than normoglycemia in
both types of HF: 20% in patients with HFpEF and 22% in
those with HFrEF (p = 0.25).
The prevalence of undiagnosed diabetes was also high, but
was less common in patients with HFpEF compared with
HFrEF (22 vs. 26%, p = 0.01). Conversely, the prevalence of
known diabetes was higher in patients with HFpEF (40 vs 35%,
p = 0.02). As a result, the prevalence of any diabetes (diagnosed
and previously undiagnosed) was 62% in each study.
HFpEF and HFrEF patients with diagnosed diabetes were at
significantly higher risk of both the primary composite outcome,
and all-cause mortality, compared with normoglycemic patients
(Figs. 1 and 2). The rates of both outcomes of interest were
Table 2 Baseline characteristics
of patients with in CHARM-
Added/Alternative with HbA1c
available, according to glycemic
status
No prior diagnosis of diabetes Prior diabetes p value
HbA1c < 6.0 HbA1c 6.0–6.4 HbA1c > 6.4 Any HbA1c
Patients, no (%) 254 (16%) 349 (22%) 417 (26%) 558 (35%)
Age, years 61 ± 13 65 ± 12 67 ± 11 64 ± 10 < 0.001
Female, n (%) 67 (26%) 93 (27%) 108 (26%) 152 (27%) 0.97
HbA1c, median (Q1–Q3) 5.6 (5.4–5.7) 6.1 (6.0–6.2) 6.7 (6.5–7.1) 8.1 (7.1–9.3) < 0.001
NYHA class, n (%) 0.028
II 93 (37%) 104 (30%) 124 (30%) 139 (25%)
III 155 (61%) 238 (68%) 278 (67%) 398 (71%)
IV 6 (2%) 7 (2%) 15 (4%) 21 (4%)
Ejection fraction 0.28 ± 0.08 0.29 ± 0.09 0.27 ± 0.08 0.27 ± 0.08 < 0.001
Heart rate, bpm 71 ± 12 72 ± 12 72 ± 12 75 ± 12 < 0.001
SBP, mmHg 125 ± 18 124 ± 19 123 ± 19 126 ± 19 0.09
BMI, kg/m2 27.9 ± 4.9 27.5 ± 5.7 28.1 ± 5.7 30.3 ± 6.1 < 0.001
eGFR, ml/min/1.73m2 81 ± 23 72 ± 24 68 ± 25 67 ± 26 < 0.001
Medical history, n (%)
Ischemic etiology 134 (53%) 212 (61%) 268 (64%) 390 (70%) < 0.001
Prior CABG 78 (31%) 112 (32%) 142 (34%) 216 (39%) 0.08
Prior PCI 42 (17%) 57 (16%) 80 (19%) 137 (25%) 0.007
Prior stroke 19 (7%) 31 (9%) 54 (13%) 63 (11%) 0.091
Prior AF 62 (24%) 92 (26%) 128 (31%) 149 (27%) 0.29
Loop diuretic 174 (69%) 258 (74%) 333 (80%) 460 (82%) < 0.001
Digoxin 165 (65%) 222 (64%) 267 (64%) 394 (71%) 0.07
β-blocker 136 (54%) 163 (47%) 232 (56%) 330 (59%) 0.003
MRA 44 (17%) 52 (15%) 93 (22%) 100 (18%) 0.06
HbA1c hemoglobin A1c, NYHA New York Heart Association functional class, SBP systolic blood pressure, BMI
body mass index, eGFR estimated glomerular filtration rate, CABG coronary artery bypass graft, PCI percutane-
ous coronary intervention, AF atrial fibrillation, MRA mineralocorticoid receptor antagonist
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higher in patients with undiagnosed diabetes and prediabetes,
compared with normoglycemic patients, p < 0.001 for trend
across dysglycemia categories for both HFpEF and HFrEF.
Discussion
We found that the prevalence of diagnosed diabetes was higher in
patients with HFpEF (40%) in CHARM than in those with
HFrEF (35%).However, the novel data in the present report relate
to the prevalence of undiagnosed diabetes and prediabetic
dysglycemia, each of which were more common than a normal
HbA1c in both HFpEF and HFrEF. Indeed, when undiagnosed
and diagnosed diabetes were combined, a remarkable 62% of
patients with each type of HF had diabetes. An additional fifth
or so of patients had prediabetes, leaving just approximately one
in six patients with a normal HbA1c, an observation that was true
for both HFrEF and HFpEF. In comparison 26% had a normal
HbA1c and 49%had either diagnosed or undiagnosed diabetes in
the Prospective Comparison of ARNI with ACEI to Determine
Impact on Global Mortality and Morbidity in Heart Failure
(PARADIGM-HF), and corresponding numbers were 30 and
41%, respectively, in the Gruppo Italiano per lo Studio della
Sopravvivenza nella Insufficienza Cardiaca-Heart Failure
(GISSI-HF) trial [10]. One explanation for the higher prevalence
in CHARM (irrespective of HF type) is that HbA1c was only
measured in North American patients where the prevalence of
diabetes is high, with the latest reports estimating that in the gen-
eral population almost 10% have diagnosed or undiagnosed dia-
betes and another 34% of the population have prediabetes [11].
As was recently reported for patients with HFrEF, undiag-
nosed diabetes and prediabetic dysglycemia in patients with
HFpEF (and HFrEF) in the present study were associated with
worse outcomes than observed in patients with a normal
Fig. 1 Adjusted risk for the primary composite outcome and all-cause mortality in CHARM-Preserved for each glycemia category
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Fig. 2 Adjusted risk for the primary composite outcome and all-cause mortality in CHARM-Alternative/Added for each glycemia category
HbA1c. Although this pattern was very similar to that reported
in the PARADIGM-HF trial, no elevated risk was reported for
patients with prediabetes in GISSI-HF. The difference in risk in
the present study was not statistically significant, probably be-
cause of the smaller number of subjects with a HbA1c mea-
surement in CHARM [7]. Although we found relative similar
prevalences of dysglycemia in patients with HFpEF and
HFrEF in the current study, the patients with these two pheno-
types differed in respect of many of their baseline characteris-
tics. Patients with HFrEF were more likely to have ischemic
etiology, worse NYHA class and were less likely to be
female. To some extent, the finding of a similarly high rate of
dysglycemia in these two quite distinct phenotypes suggests
that the syndrome of HF per se plays some role in the devel-
opment of prediabetes and diabetes. Notably, insulin resistance
is present in patients with idiopathic dilated cardiomyopathy as
well as in those with ischemic cardiomyopathy, and it is greater
in patients with coronary artery disease and HF than in patients
with coronary artery disease without HF and is not correlated
with ejection fraction [12–14]. These findings suggest that the
high prevalence of dysglycemia in HF is not explained by
recognized associations, e.g. with atherosclerosis and is related
to HF per se, independently of ventricular function.
Like PARADIGM-HF, our study has the limitation of a sin-
gle HbA1c value without a confirmatory measurement and the
additional limitation of only including patients from North
America where the prevalence of diabetes is higher than in other
geographic regions, which may introduce a selection bias and
impair applicability of our results to other regions of the world.
However, even with these limitations, our data confirm the
remarkably high prevalence of dysglycemia in HFrEF and show
that a similarly high prevalence is found in HFpEF (with only
16–18% of patients having a normal HbA1c). In both types of
HF, dysglycemia is associated with a higher risk of adverse
clinical outcomes, even before the diagnosis of diabetes. These
findings raise questions about the potential value of screening
(for undiagnosed diabetes) and treatment targeted at correcting
dysglycemia in patients with both HF phenotypes [15].
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